Humacyte (HUMA) News Today $3.58 -0.18 (-4.67%) As of 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Humacyte, Inc. (NASDAQ:HUMA) Short Interest UpdateHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 24,040,000 shares, a decrease of 6.2% from the January 15th total of 25,640,000 shares. Approximately 23.0% of the company's shares are sold short. Based on an average daily trading volume, of 4,330,000 shares, the short-interest ratio is presently 5.6 days.February 18 at 4:34 AM | marketbeat.comNorth Carolina biotech weighs demand as breakthrough treatment hits marketFebruary 12, 2025 | bizjournals.comHumacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by AnalystsFebruary 12, 2025 | americanbankingnews.comLJI Wealth Management LLC Takes Position in Humacyte, Inc. (NASDAQ:HUMA)LJI Wealth Management LLC acquired a new stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 185,000 shares of the company's stock, valued atFebruary 9, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by BrokeragesShares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have earned a consensus rating of "Buy" from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy ratingFebruary 7, 2025 | marketbeat.com83,500 Shares in Humacyte, Inc. (NASDAQ:HUMA) Acquired by Trilogy Capital Inc.Trilogy Capital Inc. acquired a new stake in Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 83,500 shares of the company's stock, valued at approximately $422,000. Trilogy Capital Inc.February 7, 2025 | marketbeat.comHumacyte and Pluristyx enhance partnership for diabetes treatmentJanuary 28, 2025 | msn.comHumacyte, Pluristyx announce expanded partnershipJanuary 28, 2025 | markets.businessinsider.comHumacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCsJanuary 28, 2025 | markets.businessinsider.comWealth Effects LLC Boosts Stake in Humacyte, Inc. (NASDAQ:HUMA)Wealth Effects LLC boosted its position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 89.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 121,400 shares of the company's stock after acquiring an additional 57,200 sharesJanuary 28, 2025 | marketbeat.comHumacyte: Upside Potential, But I Will Wait For Revenue TrendsJanuary 25, 2025 | seekingalpha.comHUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJanuary 23, 2025 | globenewswire.comBrokers Set Expectations for Humacyte FY2025 EarningsHumacyte, Inc. (NASDAQ:HUMA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Humacyte in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company will poJanuary 23, 2025 | marketbeat.comHumacyte announces planned IND filing in 2025 for sdATEV for CABGJanuary 22, 2025 | markets.businessinsider.comHumacyte moves to test bioengineered vessel in heart surgeryJanuary 22, 2025 | msn.comHumacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral CapitalD. Boral Capital reissued a "buy" rating and issued a $25.00 target price on shares of Humacyte in a report on Tuesday.January 21, 2025 | marketbeat.comHumacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass GraftingJanuary 21, 2025 | globenewswire.comCantor Fitzgerald Increases Earnings Estimates for HumacyteHumacyte, Inc. (NASDAQ:HUMA - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Humacyte in a research note issued to investors on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($1January 18, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Stock Price Up 10% - Time to Buy?Humacyte (NASDAQ:HUMA) Trading 10% Higher - Should You Buy?January 17, 2025 | marketbeat.comHUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMAJanuary 17, 2025 | globenewswire.comFaruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMAJanuary 17, 2025 | globenewswire.comCantor Fitzgerald Forecasts Stronger Earnings for HumacyteHumacyte, Inc. (NASDAQ:HUMA - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2024 earnings per share (EPS) estimates for shares of Humacyte in a report issued on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($1.40) per sJanuary 17, 2025 | marketbeat.comLevi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - HUMAJanuary 17, 2025 | prnewswire.comHumacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMAJanuary 17, 2025 | prnewswire.comHumacyte (NASDAQ:HUMA) Stock Price Down 6.4% - What's Next?Humacyte (NASDAQ:HUMA) Stock Price Down 6.4% - What's Next?January 16, 2025 | marketbeat.comHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law FirmJanuary 16, 2025 | globenewswire.comShareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class Action - HUMAJanuary 16, 2025 | globenewswire.comHumacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJanuary 16, 2025 | prnewswire.comHUMA Lawsuit Alert! Class Action Against Humacyte, Inc.January 16, 2025 | tipranks.comThe Gross Law Firm Notifies Shareholders of Humacyte, Inc.(HUMA) of a Class Action Lawsuit and an Upcoming DeadlineJanuary 16, 2025 | prnewswire.comHumacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Consensus Target Price from AnalystsShares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been given a consensus recommendation of "Buy" by the eight research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and oJanuary 16, 2025 | marketbeat.comThe Gross Law Firm Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMAJanuary 15, 2025 | globenewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of HumacyteJanuary 15, 2025 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humacyte, Inc. of Class Action Lawsuit and Upcoming Deadlines - HUMAJanuary 14, 2025 | prnewswire.comHUMA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMAJanuary 14, 2025 | globenewswire.comHumacyte (NASDAQ:HUMA) Trading Down 6.4% - Should You Sell?Humacyte (NASDAQ:HUMA) Shares Down 6.4% - Here's WhyJanuary 14, 2025 | marketbeat.comHumacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJanuary 14, 2025 | prnewswire.comContact Levi & Korsinsky by January 17, 2025 Deadline to Join Class Action Against Humacyte, Inc.(HUMA)January 14, 2025 | prnewswire.comHUMA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMAJanuary 13, 2025 | investing.comHumacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular TraumaJanuary 13, 2025 | markets.businessinsider.comHumacyte provides update on commerical launch, pricing of SymvessJanuary 13, 2025 | markets.businessinsider.comHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud LawsuitJanuary 13, 2025 | prnewswire.comHumacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJanuary 13, 2025 | prnewswire.comHumacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights – HUMAJanuary 13, 2025 | globenewswire.comHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law FirmJanuary 13, 2025 | prnewswire.comHumacyte (NASDAQ:HUMA) Receives Buy Rating from D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $25.00 target price on shares of Humacyte in a report on Monday.January 13, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of "Buy" from BrokeragesHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) has earned a consensus recommendation of "Buy" from the eight analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy ratingJanuary 13, 2025 | marketbeat.comClass Action Filed Against Humacyte, Inc. (HUMA) - January 17, 2025 Deadline to Join - Contact The Gross Law FirmJanuary 13, 2025 | prnewswire.comHumacyte, Inc. (NASDAQ:HUMA) Position Increased by Barclays PLCBarclays PLC boosted its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 177.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 236,742 shares of the company's stock after acquiring an additional 151,458 shareJanuary 13, 2025 | marketbeat.comHUMA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMAJanuary 12, 2025 | investing.com Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMA Media Mentions By Week HUMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HUMA News Sentiment▼0.980.60▲Average Medical News Sentiment HUMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HUMA Articles This Week▼29▲HUMA Articles Average Week Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TARS News Today JANX News Today AGIO News Today NAMS News Today IDYA News Today SDGR News Today TVTX News Today BLTE News Today VERA News Today IOVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HUMA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HUMA Stock Alerts